Difficulty: Medium
Average Score: 85%
Practice
A 27-year-old man has been hospitalized with fatigue and feeling sick for the past 4 months. After many tests and labs, an HIV test is performed and comes back positive. His HIV viral load is 36,000 and CD4 count is 369. He is started on multidrug therapy for his HIV disease. One of the drugs is raltegravir. What is the mechanism of action of raltegravir?
Correct answer
C
Rationale
Rationale:
The correct answer is C) Inhibits integrase.
Raltegravir is an antiretroviral drug that belongs to the class of integrase strand transfer inhibitors (INSTIs). It works by specifically targeting and inhibiting the integrase enzyme of the HIV virus. Integrase is crucial for the integration of the viral DNA into the host cell's genome, a necessary step for viral replication. By blocking integrase, raltegravir prevents the virus from replicating and spreading within the body.
Option A) Binds to viral gp41 is incorrect because gp41 is a protein involved in the fusion of the viral and host cell membranes, not the target of raltegravir.
Option B) Inhibits fusion of viral cells to CD4 cells is incorrect because fusion inhibitors like enfuvirtide target the fusion process, not integrase.
Option D) Inhibits protease is incorrect because protease inhibitors (PIs) like lopinavir target the viral protease enzyme involved in viral maturation, not integrase.
Understanding the mechanism of action of antiretroviral drugs like raltegravir is essential for healthcare professionals involved in the treatment of HIV patients. It helps in selecting the appropriate drug regimen, monitoring for efficacy, and managing potential drug interactions and side effects.
The correct answer is C) Inhibits integrase.
Raltegravir is an antiretroviral drug that belongs to the class of integrase strand transfer inhibitors (INSTIs). It works by specifically targeting and inhibiting the integrase enzyme of the HIV virus. Integrase is crucial for the integration of the viral DNA into the host cell's genome, a necessary step for viral replication. By blocking integrase, raltegravir prevents the virus from replicating and spreading within the body.
Option A) Binds to viral gp41 is incorrect because gp41 is a protein involved in the fusion of the viral and host cell membranes, not the target of raltegravir.
Option B) Inhibits fusion of viral cells to CD4 cells is incorrect because fusion inhibitors like enfuvirtide target the fusion process, not integrase.
Option D) Inhibits protease is incorrect because protease inhibitors (PIs) like lopinavir target the viral protease enzyme involved in viral maturation, not integrase.
Understanding the mechanism of action of antiretroviral drugs like raltegravir is essential for healthcare professionals involved in the treatment of HIV patients. It helps in selecting the appropriate drug regimen, monitoring for efficacy, and managing potential drug interactions and side effects.